Vitacost.com: The Online Supplement Retailer the FTC Found Making Unapproved Disease Claims Across Its Product Pages

Vitacost.com, one of the larger online retailers of dietary supplements, vitamins, and natural health products, received a joint warning from the Federal Trade Commission and the Food and Drug Administration citing disease treatment and prevention claims appearing on its product pages — claims that the agencies said were not permitted for dietary supplements under federal law and that were not backed by the level of clinical evidence required to support them in a commercial advertising context.DOCUMENTED

The warning was part of a broader joint FTC and FDA initiative targeting deceptive health claims in the supplement and natural products marketplace, particularly in the online retail channel where product pages can carry claims that would not be permissible in broadcast advertising and where the agencies had identified a pattern of retailers hosting third-party descriptions that included unsubstantiated disease claims.

The Legal Line Between Structure/Function and Disease Claims

Federal law draws a precise distinction between the claims dietary supplements may make and the claims that require drug approval. Supplements may make what the FDA calls structure/function claims — statements about how a nutrient affects the normal structure or function of the body, like 'calcium builds strong bones' or 'vitamin C supports the immune system.' What supplements may not claim without drug approval is a disease claim — a statement that the product treats, cures, mitigates, or prevents a specific disease or disease condition.DOCUMENTED

This distinction is legally clear but practically contested in product marketing, because the line between a permissible structure/function claim and an impermissible disease claim can be subtle. 'Supports healthy blood sugar levels' may be permissible; 'treats diabetes' clearly is not. But 'helps maintain blood glucose already within normal range' — language that implies a benefit for people managing blood glucose conditions — occupies contested territory that the FDA and FTC evaluate based on the context in which it appears and the consumer understanding it is likely to generate. The agencies' warning to Vitacost identified product descriptions they concluded crossed from the permissible into the impermissible side of that line.REVIEWED

Retailer Liability for Third-Party Claims

The Vitacost case raises an important issue for online supplement retailers: the extent to which a retailer is responsible for claims that appear on its platform in product descriptions originating from manufacturers, suppliers, or marketplace sellers. The FTC and FDA's joint warning to Vitacost reflected the agencies' position that a retailer who hosts and presents disease claims to consumers is responsible for those claims under the applicable legal framework, even if the description was originally written by the product's manufacturer rather than by the retailer itself.REVIEWED

This principle has significant implications for the substantial segment of the online supplement market that operates on marketplace or drop-shipping models, where retailers may carry hundreds or thousands of supplement products whose descriptions they receive from suppliers and post with limited modification. The agencies' enforcement attention to the retailer — and not only to the manufacturer — creates an obligation for retailers to review the health claims in their product catalogs and remove or modify claims that violate the applicable standards, rather than treating supplier-provided descriptions as the supplier's responsibility once they are live on the retailer's site.REVIEWED

A product page that tells a consumer a supplement will treat their condition is an advertisement — and it is the retailer's advertisement, regardless of who originally wrote the description.

The Joint FTC-FDA Initiative Context

The FTC and FDA have conducted several joint warning letter campaigns targeting deceptive supplement claims over the past several years, with particular attention to claims related to COVID-19 immunity, cancer prevention, cardiovascular disease, and metabolic health conditions including diabetes and obesity. These campaigns have reached manufacturers, retailers, and online sellers, with warning letters emphasizing the recipient's obligation to modify or remove the flagged claims within a specified period or face potential further enforcement action.DOCUMENTED

The supplement marketplace's scale — tens of thousands of products and hundreds of thousands of individual product descriptions — makes comprehensive pre-market review of health claims by the agencies impossible. The FDA does not approve supplement labels before they go to market; it can only take action after learning of a violation. The FTC's authority covers advertising deception, including online product pages, but similarly relies on post-market detection. This reactive posture means that deceptive claims can reach consumers at scale before any enforcement action occurs, which is precisely why warning letters — and the threat of further action they represent — are a primary tool for this enforcement context.

What Vitacost Was Required to Do

The joint FTC and FDA warning required Vitacost to review the flagged product pages and all other supplement product descriptions on its platform, remove or modify claims that violated the applicable standards, and confirm to the agencies that it had done so within the timeframe specified in the letter. A failure to respond or to adequately remediate the identified claims would expose Vitacost to further enforcement action by either agency — including potential FTC enforcement under Section 5 of the FTC Act for unfair and deceptive practices, or FDA enforcement under the Food, Drug, and Cosmetic Act for misbranded products.DOCUMENTED

For consumers who purchased products from Vitacost based on the disease claims in the flagged product descriptions, the warning letter does not directly create a refund mechanism or a consumer recovery process. The regulatory action is prospective — focused on removing false claims from future consumers' view — rather than compensatory for past purchasers. Consumers who purchased supplements based on claims later identified as impermissible may have recourse through class action litigation against the manufacturer or retailer, a pathway that has been used in the supplement space with some success in cases involving substantial consumer harm and clearly established claim violations.

Have documents relevant to this story? Reach us through our tips channel.